Table 1.
Baseline characteristics of 24 early breast cancer patients
| CYP2D6 phenotype | ||
|---|---|---|
| IM (n = 12) | PM (n = 12) | |
| Mean age in years (range; SD) | 52.4 (41.5–71.0; 8.7) | 53.9 (40.7–67.7; 8.0) |
| Mean BMI in kg/m2 (range; SD) | 26.7 (20.6–34.5; 4.2) | 29.4 (21.0–42.8; 6.7) |
| Menopausal status | ||
| Premenopausal | 3 | 1 |
| Postmenopausal | 8 | 11 |
| Unknown | 1 | 0 |
| Mean tamoxifen duration in months (range) | 23.3 (14.0–56.6) | 21.8 (12.0–34.7) |
| CYP2D6 genotypes | *1/*4 (n = 2) | *3/*4 (n = 2) |
| *2/*4 (n = 6) | *4/*4 (n = 7) | |
| *2/*5 (n = 2) | *4/*5 (n = 2) | |
| *4/*41 (n = 2) | *5/*6 | |
| CYP2D6 inhibitor use | 1 (venlafaxine) | 1 (paroxetine) |
IM intermediate metabolizer, PM poor metabolizer, n number of patients, SD standard deviation